CD66e (CEA) (peptide epitope) (clone EBS-CD-038), anti-human

Source:
A BALB/c mouse was immunized with human colon carcinoma cells.
Fusion partner: NS-1.



Specifications:
EBS-CD-038 recognizes a peptide epitope on CD66e or carcinoembryonic antigen (CEA), a family of proteins of 80-200 kDa. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is not found in begin glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+ from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbladder, urachus, salivary gland, ovary, and endocervix. EBS-CD-038 cross-reacts with nonspecific cross-reacting antigen (NCA; CD66c).

Species reactivity:
Positive: human.

Applications:
Demonstration of CEA peptide.
Flow cytometry: +
Frozen sections: +
Immunofluorescence: +

Positive control: MCF7 cells, 293T cells, colon carcinoma.

References:
- Muraro R, et. al. Cancer Res, 45: 5769-80 (1985).
- Siler K, et. al. Biotechn. Ther. 4(3-4): 163-81 (1993).
- Robbins PF, et. al. Int J Cancer 53(6): 892-7 (1993).
- Shi ZR, et. al. J Histochem Cytochem 42(9): 1215-9 (1994)